Skip to main content
Premium Trial:

Request an Annual Quote

Toyobo Gene Analysis to Evaluate Crucell's Cell Generation Tech

NEW YORK (GenomeWeb News) – Dutch biotech company Crucell said today that Toyobo Gene Analysis will evaluate Crucell’s cell line technology for use in producing recombinant proteins for third-party customers.
 
Toyobo Gene Analysis is a wholly-owned subsidiary of Osaka, Japan-based Toyobo.
 
Crucell’s Star Technology contains elements that “enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells,” the company said. Crucell believes this technology could be used to increase production yields of recombinant proteins, which could lower the cost of producing them.
 
Financial terms of the agreement were not released.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.